Sionna Therapeutics, Inc. (NASDAQ:SION) Receives $53.22 Average PT from Brokerages

Shares of Sionna Therapeutics, Inc. (NASDAQ:SION) have been given an average rating of “Moderate Buy” by the thirteen research firms that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, one has issued a hold recommendation, seven have given a buy recommendation and three have given a strong buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $53.2222.

Several analysts have issued reports on SION shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Friday, May 8th. Freedom Capital lowered shares of Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 20th. Wedbush assumed coverage on shares of Sionna Therapeutics in a report on Tuesday, May 5th. They issued an “outperform” rating and a $53.00 price target on the stock. JonesTrading increased their price objective on Sionna Therapeutics from $52.00 to $63.00 and gave the stock a “buy” rating in a research report on Tuesday, April 28th. Finally, Citizens Jmp reissued a “market outperform” rating and set a $63.00 price objective on shares of Sionna Therapeutics in a research note on Tuesday, May 26th.

Insider Activity

In other Sionna Therapeutics news, Director Orbimed Advisors Llc sold 184,639 shares of Sionna Therapeutics stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $46.22, for a total transaction of $8,534,014.58. Following the completion of the sale, the director directly owned 2,671,822 shares in the company, valued at $123,491,612.84. The trade was a 6.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 184,639 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $46.22, for a total transaction of $8,534,014.58. Following the completion of the transaction, the director directly owned 2,671,822 shares of the company’s stock, valued at approximately $123,491,612.84. This represents a 6.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 989,630 shares of company stock valued at $44,987,483 in the last three months. 5.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Sionna Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. bought a new stake in Sionna Therapeutics in the 3rd quarter worth approximately $30,000. BNP Paribas Financial Markets bought a new position in Sionna Therapeutics during the second quarter valued at approximately $31,000. GF Fund Management CO. LTD. purchased a new position in shares of Sionna Therapeutics during the fourth quarter worth approximately $36,000. Balyasny Asset Management L.P. bought a new stake in shares of Sionna Therapeutics in the 4th quarter worth approximately $58,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Sionna Therapeutics in the 4th quarter worth approximately $89,000.

Sionna Therapeutics Trading Up 0.7%

Sionna Therapeutics stock opened at $47.13 on Friday. The firm has a 50 day simple moving average of $41.66 and a 200 day simple moving average of $40.02. Sionna Therapeutics has a 1-year low of $16.38 and a 1-year high of $51.56. The firm has a market capitalization of $2.13 billion, a price-to-earnings ratio of -24.42 and a beta of 1.33.

Sionna Therapeutics (NASDAQ:SION) last posted its earnings results on Tuesday, May 12th. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). On average, equities research analysts forecast that Sionna Therapeutics will post -2.57 EPS for the current year.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.